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A variety of methods exist for the design or selection of antibodies and other proteins that
recognize the water-soluble regions of proteins; however, companion methods for targeting
transmembrane (TM) regions are not available. Here, we describe a method for the computational
design of peptides that target TM helices in a sequence-specific manner. To illustrate the method,
peptides were designed that specifically recognize the TM helices of two closely related integrins
(aIIbb3 and avb3) in micelles, bacterial membranes, and mammalian cells. These data show
that sequence-specific recognition of helices in TM proteins can be achieved through optimization
of the geometric complementarity of the target-host complex.
T
ransmembrane (TM) helices play essential
roles in biological processes, including
signal transduction, ion transmission, and
membrane-protein folding. Computational (1–4)
and genetic methods (5, 6) are available to
engineer antibody-like molecules that target the
water-soluble regions of proteins; however, com-
panion methods to target the TM regions are
lacking. The design of TM helices that specifi-
cally recognize membrane proteins would ad-
vance our understanding of sequence-specific
recognition in membranes and simultaneously
would provide new approaches to modulate
protein-protein interactions in membranes. Here
we describe a computational approach, desig-
nated computed helical anti-membrane protein
(CHAMP), to design peptides that specifically
recognize the TM helices of natural proteins (7).
Computational design. The design of a
CHAMP peptide requires the selection of a back-
bone geometry for the CHAMP peptide-target
complex, followed by computational selection of
the CHAMP peptide’s amino acid sequence with
a side-chain repacking algorithm. To simplify the
selection of the backbone geometry, we used the
growing database of membrane-protein struc-
tures, rather than relying on idealized helical
dimers. The majority of the TM helix-helix pairs
in TM proteins of known structure fall into a
handful of well-defined structural motifs with
recognizable sequence signatures (8). Thus, it is
possibletopredictapreferredmodeofinteraction
between a target TM helix and other TM helices
from the amino acid sequence alone. Once a
preferred mode of interaction has been identified,
examples of helix pairs from proteins of known
structure can be used as backbone conformations
for the design of a desired CHAMP peptide. The
next steps are (i) to thread the sequence of the
targeted TM helix onto one of the two helices of
the selected pair and (ii) to select the amino acid
sequence of the CHAMP helix with a side-chain
repacking algorithm (1–4, 9).
As a stringent test of the CHAMP method,
we focused on the recognition of the TM
domains of two closely related and extensively
studied platelet integrins, aIIbb3 and avb3,a s
convenient biologically important targets (10–12).
Both the aIIb and av TM helices contain a small-
X3-small motif, in which G (13)o ro t h e rs m a l l
residues (A and S) are spaced four residues apart
(14) (Fig. 1, B and C). This sequence motif is
associated with a high propensity to interact in a
tightly packed “parallel GASRight motif” (8) with
a right-handed helical crossing angle of ~ 40°.
Indeed, site-directed mutagenesis (15–17)a n d
modeling studies (15, 17, 18) suggest that the aIIb
TM helix binds the b3 TM helix with this
geometry.
Five template backbones were tested in the
design of a CHAMP peptide directed against
aIIb, and 15 were tested for av. The sequences of
aIIb and av were threaded onto either of the two
helices in each template, yielding two different
CHAMP peptides per template. A sequence for
the opposing CHAMP helix was then selected
with a Monte Carlo repacking algorithm that
considers different combinations of side chains
in low-energy rotamers (1–4, 9) [see Support-
ing Online Material (SOM)]. The rotameric
states of the side chains in the target were al-
lowed to vary, as were both the sequence and
rotamers of the CHAMP side chains. A simple
energy function that is based on a linearly
dampened Lennard-Jones potential and a mem-
brane depth–dependent knowledge-based poten-
tial (19) was then used to select the desired
residues. This knowledge-based potential as-
sured that residues with high propensities to
occupy the interfacial and fatty acyl region of
the bilayer were selected at appropriate posi-
tions. The membrane-exposed residues of the
CHAMP helix were then randomly selected
with a 60% probability of assigning L and a
10% probability of assigning A, I, F, or V.
The TM domains of av and aIIb are highly
homologous (Fig. 1, B and C), and they both
have small-X3-small motifs. Because a number
of other integrin TM helices also contain a small-
X3- s m a l lm o t i f ,as p e c i f i cC H A M Pp e p t i d em u s t
recognize not only this global feature of its target,
but also more fine-grained differences in surface
topography. In the computed complexes with the
lowest energy, the CHAMP sequences designed
against av and aIIb both have G-X3-G sequences
that create a shallow concavity that is important
for recognizing the small-X3-small sequence on
the integrin helices. However, the surrounding
sequences differ in response to differences in the
sequences of the target (Fig. 1, B and C), thereby
providing specificity.
A CHAMP peptide with extensive geomet-
ric complementarity to its target (Fig. 1D and
fig. S1) was selected based on its energy score,
the uniformity of packing of the side chains at
the CHAMP-target interface, and the ease of
synthesis. [Peptides with multiple strings of
b-branched amino acids and sequences with
particularly high predictions for amyloid (20)
were avoided.] The templates for the CHAMP
peptide-target complexes were taken from poly-
topic proteins with no functional or structural
relation to integrins, the CHAMP peptide
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 against av (anti-av) was taken from the glycerol-
3-phosphate transporter (1PW4, residues A64 to
A86 and A121 to A141) (21), and anti-aIIb was
taken from the photosystem I reaction center
(1JB0, residues L43 to L65 and L114 to L140)
(22). The designed peptides and their TM
targets (aIIb-TM and av-TM) (see SOM) were
synthesized with solubility-enhancing groups ap-
pended to the C and N termini to facilitate mem-
brane insertion (23,24).Controlpeptides,in which
the GX3G motifs were mutated (anti-aIIbmut and
anti-avmut) or scrambled (anti-aIIbscr), were also
prepared to study the specificity of the designed
sequences (Fig. 1E).
CHAMP binding in micelles. We used fluores-
cence resonance energy transfer (FRET) to eval-
uate the association of anti-aIIb with aIIb-TM
in micelles. The titration of 7-hydroxycoumarin–
tagged anti-aIIb as a FRET donor, with fluorescein-
tagged aIIb-TM as a FRET acceptor, resulted in
the quenching of the coumarin emission and the
appearance of the fluorescein emission, indicat-
ing that the two peptides interacted (Fig. 2A).
The apparent dissociation constant (Kd) for the
aIIb-TM–anti-aIIb interaction was computed to
be 0.32 ± 0.05 mM. The corresponding Kd
expressed as a mole fraction (peptide versus
detergent) is 3.2 ± 0.5× 10
−4, which is relatively
tight when compared with the range of 10
−2 (for
weak associations) to 3 × 10
−5 for very strong
associations (25), measured for TM-peptide
associations in a similar micellar environment.
Titrations with control peptides showed the
specificity of the interaction; there was neg-
ligible binding between aIIb-TM and either
anti-aIIbmut or av-TM (Fig. 2B). Furthermore,
titrations with anti-av showed that this peptide
specifically recognized av-TM (Kd = 1.3 ± 0.3 ×
10
−3 as a mole fraction), but not aIIb-TM or
anti-avmut (Fig. 2C).
Analytical ultracentrifugation of anti-aIIb and
aIIb-TM, as well as anti-av and av-TM in
micelles, indicated that these peptides formed
homodimers, as well as heterodimerizing with
their respective targets (fig. S2 and table S2).
Both CHAMP peptides heterodimerized with
Fig. 1. (A) Design of CHAMP peptides. A backbone geometry was selected for the CHAMP-target
complex; for aIIb, the template was taken from two interacting helices in a much larger protein, the
photosystem I reaction center (22). The original sequence was stripped off of the template, and the
helices were extended to span the full length of a membrane. The sequence of aIIb-TM was threaded
onto the right helix. The 14 positions selected for repacking are pink on the left helix. The final anti-aIIb
CHAMP peptide sequence is shown on the left helix with the repacked positions in pink. (B and C)
Human integrin TM targets and TM helices from homologous human integrins used in specificity
assays. The sequences (B) are modeled in an idealized helical conformation (C). Common small (G, A,
and S) residues are highlighted in red, and a common L on the binding interface is shown in purple.
(D) Close-up of the predicted tightly packed interface between anti-aIIb and aIIb-TM. aIIb-TM is
represented by a red surface with a blue hot spot. The anti-aIIb backbone is depicted in ribbon
representation, with key positions designated for computational design shown in green. (E)S e q u e n c e s
of CHAMP designs and the control peptides. The residues repacked in the anti-aIIb and anti-av
peptides are shown in pink. (Lys)2 (23) or polyethylene glycol (24) was appended to the C and N
termini as solubility-enhancing groups.
Fig. 2. Affinity and selectivity of CHAMP peptides for their target TM helices.
(A) Fluorescence emission scans of coumarin-labeled anti-aIIb (64 nM) in the
presence of different concentrations of fluorescein isothiocyanate (FITC)–
tagged aIIb- T Mi n1 0m M4 - ( 2 - h y d r o x y e t h y l ) - 1 - piperazineethanesulfonic acid
(HEPES), pH= 7.5, containing 1.0 mM C14-betaine at 25°C. (Inset) Con-
c e n t r a t i o n sa sm o l ef r a c t i o n s .lex was set at 415 nm to selectively excite the
coumarin. lex, excitation wavelength. (B) Corrected FRET signals of 64 nM
coumarin-labeled anti-aIIb (red), anti-av (green), or anti-aIIbmut (blue) in the
presence of different concentrations of FITC-tagged aIIb-TM (10 mM HEPES,
pH= 7.5, containing 1.0 mM C14-betaine at 25°C). Error bars represent SD
of the mean. (C) Corrected FRET signals of 64 nM coumarin-labeled anti-av
(green), anti-aIIb (red), or anti-avmut (orange) in the presence of different
concentrations of FITC-tagged av-TM (10 mM HEPES, pH= 7.5, containing
1.0 mM C14-betaine at 25°C). Error bars represent SD of the mean.
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 their targets at least as strongly as they homo-
dimerized. This behavior is reminiscent of
dominant-negative (DN) inhibitors of the helix-
loop-helix family of transcription regulators,
which engage in both homomeric and hetero-
meric interactions (26).
Dominant-negative TOXCAT. We next eval-
uated both the affinity and specificity of the
CHAMP peptides for their targets when coex-
pressed in bacterial membranes with a DN-
“TOXCAT” assay (Fig. 3). In TOXCAT, a TM
sequence of interest is fused to a ToxR protein
(TM-ToxR) that binds to the ctx promoter as a
dimer, which induces expression of chloram-
phenicol acetyltransferase (CAT) (27, 28). In
the DN assay, the TM1-ToxR fusion protein
is coexpressed with a second fusion protein
(TM2-ToxR*) containing a nonfunctional mu-
tant of the ToxR domain. TM-driven dimeriza-
tion leads to a ToxR-ToxR* dimer that is
unable to bind the ctx promoter or to induce
CAT synthesis (Fig. 3A). The resulting de-
crease in CAT activity can be used to monitor
the formation of a heterodimeric TM complex.
In principle, this assay could be accomplished
by adding an exogenous synthetic peptide (29);
however, it is difficult to assure that different
peptides will be similarly inserted into the
Escherichia coli inner membrane.
The anti-aIIb and anti-av peptides both
formed homodimers in bacterial membranes
(Fig. 3B) with an affinity similar to that of the
TM domain of glycophorin A (GpA), which
forms tight homodimers in this environment
(27, 28). The CAT signal for the anti-aIIb–ToxR
construct was attenuated by coexpression of
anti-aIIb–ToxR* (Fig. 3B), validating the DN
assay. When aIIb was used as the DN partner,
the signal from anti-aIIb–ToxR was also strongly
attenuated, indicative of heterodimer formation.
The magnitude of the decrease in CAT signal
due to heterodimerization of anti-aIIb with aIIb
TM is particularly notable. The homodimeriza-
tion of anti-aIIb and GpA (27, 28)a r es i m i l a ri n
affinity (Fig. 3B, first versus third bar). Thus,
because the attenuation of the CAT signal in the
DN-TOXCAT assay for an anti-aIIb–anti-aIIb
homodimer is similar to that of the anti-aIIb–aIIb
TM heterodimer (Fig. 3B, fourth versus fifth bar),
the heterodimeric TM complex anti-aIIb–aIIb has
similarly strong affinity to that of the anti-aIIb
homodimer and therefore also to the GpA
homodimer.
The TOXCATassay also shows that anti-aIIb
and anti-av are highly specific for their targets
versus other integrin TM domains. The TM do-
mains of a2, av, b1,o rb3 failed to significantly
interact with anti-aIIb, despite their high se-
quence and structural similarity to the aIIb TM
(Fig. 1, B and C). Similarly, anti-av selectively
recognized the av TM domain with much greater
affinity than the a2, aIIb, b1,o rb3 domains.
To probe whether anti-aIIb recognized its
target in the intended manner, we measured the
effect of mutating residues in anti-aIIb TM to
Fig. 3. Specificity of CHAMP
sequences in recognizing
different integrin TM regions
in a bacterial membrane. (A)
DN-TOXCAT assay. MBP,
maltose binding protein.
(B) Effect on CAT expression
of disabled ToxR* fused with
the CHAMP sequences or
different integrin TM do-
mains. The CAT expression
correlates with the homodi-
merization level of the ToxR
receptor fused with anti-aIIb
or anti-av. Error bars repre-
sent SD of the mean. (C)
Effect of mutations in the
anti-aIIb sequence on hetero-
dimerization with aIIb.B l a c k
bars represent V substitu-
tions, and gray bars repre-
sent A substitutions. Mutations
to key residues are high-
lighted according to their
buried surface area upon
dimerization (see SOM):
>75% buried (red), 50 to
75% buried (orange), and
<50% buried (green). The
percent disruption of het-
erodimerization correlates
with the predicted amount
of area buried upon dimer-
ization, indicating that the
anti-aIIb CHAMP peptide recognizes aIIb-TM, as in the designed complex. Error bars represent SD of
the mean.
Fig. 4. Anti-aIIb activates
aIIbb3,a n da n t i - av activates
avb3 in human platelets. (A)
Schematic diagram of integrin
regulation. Because the a
and b subunit TM domains
interact when integrins are
inactive, any process that
destabilizes this interaction
w o u l db ee x p e c t e dt oa l -
low dissociation of the TM
domains with concomitant
integrin activation. In plate-
l e t s ,t h i so c c u r sw h e nt h e
platelets are stimulated by
agonists such as ADP. CHAMP
peptides destabilize this inter-
action by blocking the interac-
tions between the TM helices
of the a and b subunits. (B)
Fibrinogen-mediated aggre-
gation of gel-filtered human
platelets was measured in a turbidometric aggregometer after the addition of either 0.5 mMa n t i - aIIb or
10 mMa n t i - av. To differentiate between a direct effect of anti-aIIb on aIIbb3 versus anti-aIIb–stimulated
signal transduction, anti-aIIb–induced platelet aggregation was also measured in the presence of 2 mM
PGE1,1 0u n i t s / m la p y r a s e ,1m MR G D S ,o r2 . 5m ME D T A .( C) Platelet adhesion to the wells of
microtiter plates coated with osteopontin was measured in the presence of 20 mMA D P ,1 0mMa n t i - av,
and 2 mMa n t i - aIIb.T h ed a t as h o w na r et h em e a na n dS E Mo fm e a s u r e m e n t sm a d ei nt r i p l i c a t e .O D ,
optical density.
www.sciencemag.org SCIENCE VOL 315 30 MARCH 2007 1819
RESEARCH ARTICLES
 
o
n
 
F
e
b
r
u
a
r
y
 
9
,
 
2
0
0
8
 
w
w
w
.
s
c
i
e
n
c
e
m
a
g
.
o
r
g
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 either V or A (Fig. 3C). Mutations to the res-
idues predicted to occur at the helix-helix inter-
face caused disruption of heterodimer formation.
Very large effects were observed for buried
residues within a 10-residue stretch (residues 11
to 20) spanning the primary interaction site,
whereas only minor effects were observed for
residues on the non-interacting side of the helix
or the more distal sites (residues 23 and 24).
Interestingly, the interaction face resembles a
“Gly-zipper” (GX3GX3G) motif that has re-
cently been shown to mediate intermolecular
helix-helix associations in membranes (30).
Platelet aggregation and adhesion. To
determine whether exogenously added CHAMP
peptides recognize their targets in mammalian
cells, we first determined whether they were
capable of inserting into phospholipid bilayers
without perturbing the integrity of the mem-
brane. The addition of anti-av or anti-aIIb to
phospholipid vesicles led to a large blue shift
in the peptide’s W fluorescence spectrum, in-
dicative of insertion into the hydrophobic region
of bilayers (fig. S3). Furthermore, circular di-
chroism spectroscopy showed that the vesicle-
bound peptides were helical (fig. S4), and at-
tenuated total reflectance–infrared spectroscopy
revealed that they adopted a transmembrane
orientation, with their helix perpendicular to the
bilayer surface (fig. S5). Moreover, anti-aIIb and
anti-av did not lyse human erythrocyte mem-
branes at the concentrations that were used in
the following assays (fig. S6).
Pharmacological studies indicated that the
CHAMP peptides interact with their target
integrins in mammalian cells. The aIIbb3 and
avb3 integrins are heterodimers whose a and b
subunits are composed of a large extracellular
domain, a TM helix, and a short cytoplasmic
domain. In the resting state, the TM helices of
their a and b subunits interact (15–18)( 18),
whereas they separate when the integrins are
activated by mutations or after treatment of cells
with pharmacological agonists (15–18). Thus,
the binding of a CHAMP peptide to the ap-
propriate site on the TM helix of aIIb or av
shoulddisruptdimerizationwiththeb3TMhelix,
thereby shifting the conformational equilibrium
oftheintegrintowarditsactivatedstate(Fig.4A).
In platelets, aIIbb3 is in several-hundred–fold ex-
cess over avb3. Thus, a successful anti-avpeptide
mustrecognize itstargetin thepresenceofalarge
excessofacloselyrelatedintegrin,andtheanti-aIIb
peptide must bind its target without affecting a
minor population of avb3.
The physiological role of aIIbb3 is to induce
platelet aggregation, which occurs through an
interaction with its divalent ligand, the plasma
protein fibrinogen. Anti-aIIb rapidly induced
platelet aggregation (Fig. 4B) in a dose-
dependent manner when added at concentrations
from 75 nM to 500 nM (fig. S7). Anti-aIIb–
inducedaggregationwasonlyminimally affected
by the platelet inhibitor prostaglandin E1 (PGE1)
and by the adenosine 5´-diphosphate (ADP)
scavenger apyrase, which indicated that it was
independent of platelet signal transduction or se-
creted ADP. Furthermore, anti-aIIb–induced ag-
gregation was inhibited by agents that inhibit the
function of aIIbb3’s fibrinogen-binding site (Fig.
4B), including EDTA or the peptide RGDS (10).
In contrast, no platelet aggregation occurred
when the platelets were exposed to 10 mMa n t i -
av, which demonstrated that this peptide did not
activate aIIbb3.
The integrin avb3 mediates the adhesion of
platelets to the matrix protein osteopontin, po-
tentially exposed to the circulating blood by
rupture of an atherosclerotic plaque. Incubating
platelets with anti-av induced robust platelet ad-
hesion to osteopontin (Fig. 4C), even in the
absence of pharmacological platelet agonists. As
expected from the FRET binding curves (Fig.
2C), the potency of anti-av in inducing platelet
adhesion to osteopontin was lower by a factor
of 10 than that of anti-aIIb in inducing platelet
aggregation (fig. S9). Anti-av–induced adhe-
sion was prevented by agents that inhibit the
interaction of avb3’s extracellular ligand-binding
site with osteopontin, including EDTA or the
specific RGD-containing avb3 antagonist XJ735,
which confirmed that anti-av–induced platelet
adhesion to osteopontin is mediated by avb3.
Notably, there was no platelet adhesion to
osteopontin when platelets were incubated with
anti-aIIb at concentrations that fully activate
aIIbb3 ( F i g .4 C ) ,a n da n t i - aIIbmut and anti-avmut
hadnegligible effectsin activating eitherintegrin.
Thus, these experiments indicate that anti-a
v can
specifically recognize and activate avb3 in the
presence of a 400-fold excess of aIIbb3.
Rupture force spectroscopy. One potential
ambiguity with the platelet experiments is that
membrane peptides are intrinsically sticky,
which could lead to nonspecific interactions that
might cloud the interpretation of the results.
Furthermore, the TM helices of integrins might
engage in a number of homomeric interactions
or heteromeric interactions with other membrane
proteins (15–18), which may cause avidity
effects relating to clustering and mutivalent
binding. Therefore, to measure the interaction
at the single-molecule level, we used laser
tweezers–based force spectroscopy to evaluate
the activity and selectivity of anti-aIIb and anti-av
Fig. 5. Rupture force
spectroscopy (laser tweez-
ers) was used to measure
the effect of anti-aIIb and
anti-av on platelet aIIbb3
and avb3 at the level of
single molecules. The his-
tograms represent the
distribution of mea-
sured rupture forces be-
tween platelets and beads
coated with (A)f i b r i n o -
gen, an aIIbb3 ligand, or
(B)o s t e o p o n t i n ,a navb3
ligand. Rupture forces in
(A) were measured in
the presence of 0.5 mM
anti-aIIb,0 . 5mMa n t i - aIIb
and the aIIbb3 antago-
nist abciximab, 0.5 mM
anti-aIIbscr, and 10 mM
anti-av. Rupture forces in
(B) were measured in the
presence of 10 mMa n t i - av,
10 mMa n t i - av and the
avb3 antagonist XJ735,
10 mMa n t i - avmut, and
0.5 mMa n t i - aIIb.
30 MARCH 2007 VOL 315 SCIENCE www.sciencemag.org 1820
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 in platelets. The spectrum of rupture forces re-
quired to detach an osteopontin- or fibrinogen-
coated bead from a platelet provides a measure of
the ability of the CHAMP peptides to activate
their target integrin and of the integrin to interact
with its appropriate ligand. Histograms of rupture
forces collected for a large number of contacts
between platelets and ligand-coated beads are
shown in Fig. 5. In the absence of CHAMP
peptides, the binding probability decreased
exponentially with increasing force, indicative
of a nonspecific interaction (31). However, in the
presence of 0.5 mM anti-aIIb (Fig. 5A), a peak is
observed at a position similar to that observed
when aIIbb3 is stimulated by platelet agonists
(31). The peak was eliminated by addition of the
aIIbb3-specific antibody, abciximab, which blocks
the fibrinogen-binding site on the extracellular
domain of aIIbb3. Thus, the highly adhesive inter-
action between platelets and fibrinogen is medi-
ated by activated aIIbb3.
Exposing platelets to 10 mMa n t i - avproduced
a peak of rupture force between platelets and
osteopontin-coated beads with a maximum at
~45 pN(Fig.5B), characteristic of the interaction
of avb3 and osteopontin-coated beads (32). This
anti-av–induced activation was eliminated by the
avb3 antagonist XJ735. There was no peak of
specific rupture force between the platelets and
the osteopontin-coated beads when the platelets
were exposed to concentrations of anti-aIIb that
fully activate aIIbb3 (Fig. 5B, bottom panel).
Demonstrating the specificity of the interaction,
anti-av failed to induce adhesion to fibrinogen-
coated beads (Fig. 5A, bottom panel), and both
anti-aIIbscr (Fig. 5A) and anti-avmut (Fig. 5B)
had negligible effects on the activation of either
integrin. Thus, by activating specific integrin func-
tions, these experiments confirm that anti-aIIb
and anti-av can specifically interact with aIIb and
av in situ in the plasma membrane of platelets.
Discussion. Lateral TM helix-helix associa-
tions play essential roles in membrane-protein
folding, assembly, and signal transduction (33);
what defines the specificity for their assembly
(8)? For TM motifs similar to those studied
here, there is only a 3 to 5 kcal/mol energetic
difference (a factor of about 100 to 10,000)
between a strongly associating TM helix dimer,
such as GpA, and the nonspecific dimerization
of randomly associating TM helices in micelles
(25). For this class of helix-helix interaction
motifs, nature appears to achieve this modest
energetic difference by (i) optimizing the
geometric fit (34–36), electrostatic interactions,
and weak C–H···O=C hydrogen bonds (37)
between the two interacting helices and (ii) po-
sitioning the interacting sites on the two helices
at precisely the same region of the bilayer.
Similar specificity can now be engineered from
first principles.
Given that there is only a small energetic
difference between randomly associating TM
helices and natural high-affinity dimers, it might
appear that the design of a CHAMP peptide
would require highly accurate computation of
the enthalpy and entropy of peptide-peptide and
peptide-phospholipid interactions. These cal-
culations would require consideration of com-
putationally challenging interactions, such as
interhelical C–H···O=C hydrogen bonds (37)
and local deviations from ideal helical geometry
required to facilitate association of the helices.
We largely circumvent the need for such ac-
curacy by using a library of structurally defined
helix pairs that are already in local minima with
respect to interhelical backbone-backbone inter-
actions and that position side chains for appro-
priate pairwise interactions. The problem then
simplifies to selecting the best backbone from
this library for the construction of a CHAMP
peptidethatmaximizesthegeometriccomplemen-
taritybetweentheCHAMPpeptidesequenceand
its target. Although our scoring function for
sequence selection is quite simple and we used
only a subset of the available helix pairs, the
procedureappearstobehighlyeffective.Thefirst
two peptides designed with this protocol are
described in this paper, whereas a third is de-
scribed in the SOM. On the basis of this very
limited sampling of three peptides, the method
has been 100% successful.
The CHAMP design procedure is highly
sensitive to the fine-grained topographic differ-
ences between the targets, which is consistent
with the hypothesis that geometric complemen-
tarity is critical for tight and specific recognition.
Although the sequences of the TM helices of
aIIb and av are similar, the sequences of anti-aIIb
and anti-av differ substantially, resulting in dif-
ferent selectivities. For example, anti-aIIb has a
Gly-zipper motif (30), which is essential for the
recognition of aIIb, whereas anti-av has an M
rather than the third G in this motif.
It should be possible to extend the CHAMP
approach to other TM helix-association motifs,
including ones involving polar side chains,
which provide a strong driving force for helix-
helix association (33). In this case, we would
search for a helix pair library with structures in
which one helix has the polar side chain(s) of
interest and the second helix has appropriate
side chains to bind it (38). Furthermore, the
method could be modified to consider multispan
bundles, rather than dimers, or to use “negative”
design to select for sequences that avoid
undesirable interactions; it should be possible
to include a scoring function to avoid sequences
that are particularly prone to amyloid formation
(20), or one could computationally screen target
CHAMP sequences against undesired targets to
minimize off-target binding.
The activity of these CHAMP peptides is
consistent with a push-pull mechanism of
integrin activation, which postulates that sepa-
ration of the a and b TM helices is a dominant
signal for integrin activation (15, 17, 39). In this
mechanism, integrins are activated by any per-
turbation that physically pushes the integrin TM
helices apart (e.g., mutations that disrupt the a-b
TM interface) or that pulls them apart via
binding interactions that preferentially stabilize
the separated state: CHAMP peptides activate
by binding to a site in the a TM helix that
physically blocks its interaction with the b TM
helix, the binding of talin to the membrane-
proximal cytoplasmic domain of the b subunit
appears to impede its interactions with the a
subunit (40), and the homo-oligomerization of
the TM domains might activate by competing for
heteromeric TM helix-helix associations (17).
More generally, CHAMP peptides should
provide important reagents to probe the func-
tional consequences of blocking protein-protein
interactions in membranes, in a manner similar
to the use of antibodies to study water-soluble
regions of proteins. Previous investigators have
shown that peptides from the TM regions of
oligomeric proteins can disrupt the lateral as-
sembly of the native complex (41–43). How-
ever, high concentrations of these TM peptides
were required to elicit partial effects. Similarly,
we have found that peptides from the TM re-
gions of aIIb and b3 are substantially weaker
activators of aIIbb3 activation than anti-aIIb (44).
It is likely that the affinity and specificity of the
CHAMP peptides designed in this work could
be further improved by genetic methods used
previously for investigating membrane-peptide
recognition (45), in a process similar to affinity
maturation of antibodies. Given the growing
appreciation of lateral TM helix associations in
membrane-protein folding, assembly, and signal
transduction (33), CHAMP peptides will pro-
vide much needed reagents for probing these
processes.
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Early Optical Polarization of a
Gamma-Ray Burst Afterglow
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We report the optical polarization of a gamma-ray burst (GRB) afterglow, obtained 203 seconds
after the initial burst of g-rays from GRB 060418, using a ring polarimeter on the robotic Liverpool
Telescope. Our robust (2s) upper limit on the percentage of polarization, less than 8%, coincides
with the fireball deceleration time at the onset of the afterglow. The combination of the rate of
decay of the optical brightness and the low polarization at this critical time constrains standard
models of GRB ejecta, ruling out the presence of a large-scale ordered magnetic field in the
emitting region.
G
amma-ray bursts are the most instanta-
neously powerful explosions in the
universe and represent the most impor-
tant new astrophysical phenomenon since the
discovery of quasars and pulsars. Identified as
brief, intense, and unpredictable flashes of high-
energy g-rays on the sky, the most common type
of GRB, so-called long bursts, have g-ray pulses
that last longer than 2 s. These are thought to be
produced when a massive star reaches the end of
its life, its core collapsing to form a black hole
and, in the process, ejecting an ultrarelativistic
blastwave (1, 2). In many cases, the detected
g-rayfluximpliesanunphysicallyhighexplosion
energy if assumed to be emitted isotropically by
the source, the so-called energy catastrophe.
Instead, focusing the energy into a narrow jet
reduces the intrinsic energy output to a canonical
~10
51 erg for most GRBs (3).
Aftertheinitialburstofg-rays,thesubsequent
radiation produced at longer wavelengths (e.g.,
x-ray,optical,orradio),termedthe“afterglow,”is
generally accepted to be synchrotron radiation
whose observed properties are consistent with a
focused jet expanding at ultrarelativistic speeds
into the interstellar medium. The production of
synchrotron radiation requires the presence of a
magnetic field, but the origin and role of the
magneticfieldsinGRBejectaarealong-standing
open issue. In turn, fundamental questions on the
driving mechanism of the explosion, in particu-
lar, whether the relativistic outflow is dominated
by kinetic (baryonic) or magnetic (Poynting flux)
energy, remain unanswered (4, 5). The primary
challenges in addressing these issues arise
because GRBs are short-lived, compact, and lie
atvastcosmologicaldistances;ourunderstanding
of their physical nature is therefore inferred from
the characteristics of their radiation, measured at
the earliest possible time when the observed
radiation is still sensitive to the properties of the
original fireball.
The two main models of collimated rela-
tivistic outflows, or jets, that have been proposed
are the hydrodynamical and the magnetized jet
(5). Hydrodynamical jets have no dominant
ordered magnetic field but instead produce
synchrotron radiation from tangled magnetic
fields, concentrated in the thin layer of the
expanding shock front, that are generated locally
by instabilities in the shock (6); the magnetic
field does not influence the subsequent evolution
of the jet. Models of these jets have been highly
successful at reproducing a wide range of ob-
served properties of GRBs (1, 2). A relativistic
outflow from a central engine might have a weak
ordered or random magnetic field. As long as the
magneticfielddoesnotaffectthedynamicsofthe
jet, we classify it as a hydrodynamical jet. In
contrast, magnetized jets are threaded with
strong, globally ordered magnetic fields, which
originate at the central source, are advected out-
wardwiththe expandingflow,andmayprovidea
powerful mechanism for collimating and accel-
erating the relativistic jet (7, 8). A magnetic
driving mechanism is an attractive scenario to
account for the prodigious energy outputs and
vast accelerations required for GRB ejecta, as
well as for overcoming energy-efficiency prob-
lems inherent in hydrodynamical models in
which internal shocks must convert kinetic
energy to radiative energy with sufficient effi-
ciency to produce the observed g-ray emission
and prolonged central engine activity (9, 10).
Observationally, the fading rate of the after-
glow emission alone is inadequate asa diagnostic
for distinguishing between these theoretical jet
models (11–13); in contrast, the polarization
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